Identity
- Security key
- 24000
- Ticker
- XRTX
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2018-05-04
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- XRTX
Detail
Enriched 2026-08-14 20:47
- Market cap
- $3,739,750.97
- Shares outstanding (class)
- 1,816,565
- Shares outstanding (weighted)
- 1,730,565
- SIC
- —
- Employees
- 3
- Location
- —
- Homepage
- https://www.xortx.com
- Description
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
Market cap and share counts drift.